News

MedImmune joins research collaboration with the University of California

MedImmune joins research collaboration with the University of California

17-02-2014

MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

Antibiotics and Infectious diseasesCardio-vascularInflammatory diseasesMedImmuneMetabolicsNeurologicalOncologyPharmaceuticalResearchRespiratory and PulmonaryUSA

AstraZeneca's Brilinta gains Class I in ACCF/AHA Guidelines; enters deal with Progenics

18-12-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced yesterday that a combined panel of experts…

Antibiotics and Infectious diseasesAstraZenecaBrilintaCardio-vascularLicensingMedImmunePharmaceuticalProgenics PharmaceuticalsRegulation

PDL BioPharma to pay MedImmune $92.5 million to resolve patent disputes; Mylan debuts generic Vfend

17-02-2011

PDL BioPharma (Nasdaq: PDLI) saw its shares drop 3.5% to $5.25 after the company said it had entered…

Antibiotics and Infectious diseasesAstraZenecaFinancialGenericsMedImmuneMylan LaboratoriesNorth AmericaPatentsPDL BioPharmaPfizerPharmaceuticalRespiratory and PulmonarySynagisVfend

AstraZeneca’s MedImmune unit in licensing deal with Phylogica for antimicrobial peptide

20-08-2010

Australian drug discovery firm Phylogica (ASX: PYC, XETRA: PH7) has entered into an agreement with Anglo-Swedish…

Antibiotics and Infectious diseasesAstraZenecaLicensingMedImmunePharmaceuticalPhylogicaResearch

Back to top